Ascendiant Capital Markets Increases NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $44.00

NRx Pharmaceuticals (NASDAQ:NRXP) had its target price hoisted by Ascendiant Capital Markets from $43.00 to $44.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright boosted their price objective on NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a buy rating in a research report on Monday, August 5th.

NRx Pharmaceuticals Trading Down 4.4 %

NRXP opened at $1.72 on Thursday. The company has a market cap of $18.41 million, a price-to-earnings ratio of -0.55 and a beta of 1.25. The company’s fifty day moving average price is $2.04 and its two-hundred day moving average price is $10.85. NRx Pharmaceuticals has a 1-year low of $1.59 and a 1-year high of $7.33.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.06. As a group, equities analysts forecast that NRx Pharmaceuticals will post -3.25 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. AdvisorShares Investments LLC acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 642,632 shares of the company’s stock, valued at approximately $296,000. AdvisorShares Investments LLC owned approximately 0.75% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.